The ASCO 2026 presentation on May 30 is the next major catalyst — positive data could drive significant upside given the $11M market cap. However, massive dilution from 89.6M warrants and 103M fully diluted shares caps near-term upside. Monitor for partnership or licensing deals given extended cash runway.
Price Chart
Executive Summary
Aprea Therapeutics reported Q1 2026 results with a net loss of $3.3M ($0.22/share), narrower than the $3.9M loss in Q1 2025. The company highlighted a confirmed partial response in its Phase 1 ACESOT-1051 trial for WEE1 inhibitor APR-1051 and closed a $30M oversubscribed private placement, extending cash runway into Q1 2028. The combination of clinical progress and strengthened balance sheet is positive, but the company remains a pre-revenue clinical-stage biotech with no approved products.
Key Financial Metrics
Key Facts
- Net loss of $3.3M ($0.22/share) for Q1 2026 vs $3.9M ($0.66/share) in Q1 2025
- Cash and cash equivalents of $46.5M as of March 31, 2026, up from $14.6M at Dec 31, 2025
- Closed oversubscribed $30M private placement led by Soleus Capital on March 31, 2026
- Confirmed partial response (PR) in ACESOT-1051 trial for APR-1051 in PPP2R1A-mutated uterine carcinosarcoma
- ASCO 2026 abstract accepted; poster presentation on May 30, 2026
- Cash runway extended into Q1 2028
- Operating loss improved to $3.4M from $4.1M in Q1 2025
- R&D expenses decreased to $1.6M from $2.5M due to paused ATRN-119 trial
- Fully diluted share count of 103.1M common equivalents as of May 13, 2026
Financial Impact
Cash position strengthened from $14.6M to $46.5M via $30M private placement; net loss improved 16% YoY to $3.3M
Risk Factors
- Massive dilution: 89.6M warrants outstanding vs 12.4M common shares outstanding
- Pre-revenue clinical-stage company with no approved products
- ATRN-119 program paused; all focus on single asset APR-1051
- Early-stage clinical data may not translate to registrational trials
- S-3 shelf filed April 2026 allows resale of 74.3M shares by selling stockholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-059734 |
| Document: apre-20260513xex99d2.htm | 0001104659-26-059734 |
| Document: apre-20260513x8k.htm | 0001104659-26-059734 |
| Document: 0001104659-26-059734-index-headers.html | 0001104659-26-059734 |
| Document: 0001104659-26-059734-index.html | 0001104659-26-059734 |
| Document: 0001104659-26-059734.txt | 0001104659-26-059734 |
| 8-K Data (Synthetic) | 0001104659-26-059734 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers